Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GetRelief Rx vs Luma Health Co

GetRelief Rx
Graded #353

Lower grade

vs+16.1
Luma Health Co
Graded #59

Higher grade

The verdict

Luma Health Co takes it — 75/100 to 58.9/100.

Luma Health Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luma Health Co is a nurse-practitioner-led virtual weight-loss and wellness clinic founded by Tiffani McKnight, FNP-C.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuma Health Co +26
43
69
Dose & formulationGetRelief Rx +9
78
69
Clinical oversightLuma Health Co +13
70
83
Labs & monitoringLuma Health Co +45
52
97
FulfillmentLuma Health Co +12
58
70
Contract termsLuma Health Co +8
47
55
GetRelief Rx · left barLuma Health Co · right bar

The numbers

MetricGetRelief RxLuma Health Co
WeighScore58.9/10075/100
GradeCC
Scorecard rank#353#59
Semaglutide$269/mo (9 mg dose, compounded oral)$120/mo (plus a separate fee, compounded)
Tirzepatide$179/mo (16 mg dose, compounded oral)$180/mo (compounded)
CoverageCoverage not published30 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
GetRelief Rx

Graded #353 · C

Strengths

  • Compounded semaglutide and tirzepatide priced publicly — no login required to see costs
  • BBB accredited with an A rating (March 2026)
  • Free online assessment with no upfront consultation fee

Where it loses points

  • Sublingual drops only — no injectable; this delivery method wasn't studied in the STEP/SURMOUNT trials
  • Still sells compounded tirzepatide after the FDA ended compounding enforcement discretion in 2025
  • No LegitScript, PCAB, or NABP pharmacy certifications found
  • Prescriber credentials listed only as 'licensed clinicians' with no detail on degree type
Luma Health Co

Graded #59 · C

Strengths

  • Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
  • No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
  • Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
  • Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
  • HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission

Where it loses points

  • Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
  • Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
  • Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
  • Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard